AstraZeneca’s Phase III FLAURA2 trial shows positive result
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Rhonda Pacheco to succeed Julie Kim, who was appointed to be Takeda’s next CEO
AHLL will become a 100% subsidiary of AHEL with 99.42% held by AHEL and balance in the ESOP pool
Both will develop a non-viral manufacturing workflow designed to eliminate key bottlenecks and accelerate the delivery of lifesaving engineered cell therapies to patients
CRISPR-based detection enables highly specific molecular recognition
Four FDA-approved products strengthen portfolio and reaffirm commitment to global reach
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Maria Soler Nunez appointed as Chief Quality Officer
Subscribe To Our Newsletter & Stay Updated